Enanta Pharmaceuticals, Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| RenTech | quant | 665.3K | $8.40M | 0.01% | Added+3.6% | 2026-03-31 |
| StateStreet | passive | 562.1K | $7.10M | 0.00% | Added+7.3% | 2026-03-31 |
| TwoSigma | quant | 267.4K | $3.38M | 0.00% | Trimmed-6.3% | 2026-03-31 |
| Wellington | fundamental | 75.0K | $946.75K | 0.00% | Added+18.6% | 2026-03-31 |
| DEShaw | quant | 70.9K | $895.26K | 0.00% | Trimmed-57.7% | 2026-03-31 |
| FidelityFMR | fundamental | 27.3K | $344.45K | 0.00% | Added+532.5% | 2026-03-31 |
| TRowePrice | fundamental | 18.7K | $237 | 0.00% | Added+29.8% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-10upcoming | -0.45 | — | — |
| 2026-05-11 | -0.49 | -0.45 | +7.79% |
| 2026-02-09 | -0.88 | -0.42 | +52.05% |
| 2025-11-17 | -1.01 | -0.87 | +13.86% |
| 2025-08-11 | -0.88 | -0.85 | +3.95% |
| 2025-05-12 | -1.14 | -1.06 | +6.67% |
| 2025-02-10 | -1.35 | -1.05 | +22.37% |
| 2024-11-25 | -0.92 | -1.36 | -47.83% |
| 2024-08-05 | -1.41 | -1.07 | +24.11% |
| 2024-05-06 | -1.40 | -1.47 | -4.70% |
| 2024-02-07 | -1.23 | -1.58 | -28.87% |
| 2023-11-20 | -2.21 | -1.33 | +39.89% |
| 2023-08-07 | -2.19 | -1.86 | +15.15% |
| 2023-05-08 | -1.93 | -1.79 | +7.09% |
| 2023-02-07 | -1.60 | -1.39 | +13.03% |
| 2022-11-21 | -1.35 | -1.27 | +6.04% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ENTA | -8.29% | -10.60% | -16.55% | +121.92% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -11.26% | -5.96% | -13.11% | +109.23% |